Humboldt Fund

Deciduous Therapeutics is an aging therapeutics company developing a novel class of immune-modulatory therapies that clear senescent cells and promote a healthy lifespan. Deciduous is led by Anil Bhushan, a professor at UCSF, and Robin Mansukhani, a five-time biotech founder.

Endpoint Health, Inc. researches and develops therapies by combining therapeutics, companion diagnostics, and artificial intelligence into an integrated platform. It develops therapies to improve the outcomes of patients with critical illnesses, such as sepsis, acute respiratory distress syndrome, and COVID-19. Endpoint Health, Inc. was founded in 2018 and is headquartered in Palo Alto, California. It has additional offices in Detroit and Livonia, Michigan; and Chicago, Illinois.

Ansa Biotechnologies, Inc. is a biotechnology company based in Berkeley, California, focused on developing innovative DNA synthesis technology utilizing enzymes. Established in 2018, the company aims to improve upon traditional chemical methods of DNA synthesis that have remained largely unchanged for decades. Ansa's enzymatic approach offers significant advantages, including increased speed, accuracy, and cleanliness in the production of DNA fragments such as oligonucleotides. This technology enhances the capabilities of biological research, therapeutics, diagnostics, and biomanufacturing by enabling the synthesis of gene-length oligonucleotides. Through its advancements, Ansa Biotechnologies seeks to facilitate innovation in the fields of biological research and engineering, ultimately providing valuable services to medical researchers and contributing to the broader biotechnology landscape.

Finless Foods Inc. is a biotechnology company based in Emeryville, California, focused on producing sustainable seafood alternatives through cellular agriculture technologies. Founded in 2017, the company specializes in growing marine-animal cells to create seafood products, including bluefin tuna. Finless Foods aims to provide a healthier and environmentally friendly alternative to traditionally caught and farmed seafood, offering consumers a cost-effective option that does not compromise on taste or dietary preferences. The company's mission is to develop and mass manufacture innovative marine animal food products that promote sustainability and accessibility in the seafood market.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other serious age-related conditions. The company specializes in precision pharmaceuticals, creating innovative genetic treatments that are selectively targeted to specific tissues and cells. HAYA Therapeutics employs a discovery engine that identifies tissue- and cell-specific drivers of fibrosis and other disease processes by leveraging non-coding RNAs in the human genome. Through its biopharmaceutical therapies, HAYA Therapeutics seeks to block myocardial fibrosis, offering potential new options for the management of heart failure and related disorders.

Cellino Biotech, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in intracellular delivery lasers and nanotechnology specifically for gene editing applications. The company has developed an AI-guided laser editing platform that automates the generation of personalized, autologous cell therapies, significantly reducing the development time of engineered cells from years to weeks. By integrating advanced tools from optics, biology, and computation, Cellino makes stem cell differentiation a digital process, allowing healthcare providers to efficiently produce functionally mature cells at scale. This innovative approach aims to enhance the accessibility of life-saving medicines for patients.

Ansa Biotechnologies, Inc. is a biotechnology company based in Berkeley, California, focused on developing innovative DNA synthesis technology utilizing enzymes. Established in 2018, the company aims to improve upon traditional chemical methods of DNA synthesis that have remained largely unchanged for decades. Ansa's enzymatic approach offers significant advantages, including increased speed, accuracy, and cleanliness in the production of DNA fragments such as oligonucleotides. This technology enhances the capabilities of biological research, therapeutics, diagnostics, and biomanufacturing by enabling the synthesis of gene-length oligonucleotides. Through its advancements, Ansa Biotechnologies seeks to facilitate innovation in the fields of biological research and engineering, ultimately providing valuable services to medical researchers and contributing to the broader biotechnology landscape.

Compound Foods creates coffee without coffee beans

Compound Foods creates coffee without coffee beans

Debut Biotechnology, Inc. is a biotechnology company based in San Diego, California, established in 2019. It specializes in biomanufacturing solutions for high-value molecules, focusing on the development of specialty enzyme solutions and continuous manufacturing processes. The company offers a range of services, including biomanufacturing cartridges, fermentation, and the immobilization of cells and enzymes. Debut Biotechnology is dedicated to creating novel immobilization techniques for enzymes, achieving high success rates and providing immobilized enzymes for continuous manufacturing systems. Its innovative approach enables the production and modification of small and large molecules, catering primarily to the pharmaceutical and specialty chemical industries. By harnessing natural enzyme technologies, Debut aims to deliver sustainable and cost-effective ingredient solutions to its clients.

Debut Biotechnology, Inc. is a biotechnology company based in San Diego, California, established in 2019. It specializes in biomanufacturing solutions for high-value molecules, focusing on the development of specialty enzyme solutions and continuous manufacturing processes. The company offers a range of services, including biomanufacturing cartridges, fermentation, and the immobilization of cells and enzymes. Debut Biotechnology is dedicated to creating novel immobilization techniques for enzymes, achieving high success rates and providing immobilized enzymes for continuous manufacturing systems. Its innovative approach enables the production and modification of small and large molecules, catering primarily to the pharmaceutical and specialty chemical industries. By harnessing natural enzyme technologies, Debut aims to deliver sustainable and cost-effective ingredient solutions to its clients.

Mission Barns, Inc., founded in 2018 and based in Berkeley, California, specializes in producing cell-cultured meat from animal cells. The company cultivates animal cells in a nutrient-rich environment, allowing for the sustainable growth of meat while minimizing the negative impacts associated with traditional animal farming. By leveraging advancements in biotechnology and food science, Mission Barns aims to provide juicy and savory meat products in a more efficient and environmentally friendly manner. The company's approach is designed to contribute to a more sensible food system, addressing the growing demand for sustainable food solutions.

Meatable B.V. is a food production company based in the Netherlands that specializes in the development of lab-grown meat and meat products derived from cows, chickens, and pigs. Founded in 2018, the company focuses on producing single-cell based hamburgers and aims to address concerns related to climate change, animal welfare, and food security. By utilizing innovative techniques, Meatable seeks to provide a sustainable alternative to traditional meat production, allowing consumers to enjoy real meat without compromising ethical or environmental standards. Through its efforts, the company aspires to satisfy the global demand for meat while promoting a more responsible and guilt-free approach to food consumption.

Cellino Biotech, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in intracellular delivery lasers and nanotechnology specifically for gene editing applications. The company has developed an AI-guided laser editing platform that automates the generation of personalized, autologous cell therapies, significantly reducing the development time of engineered cells from years to weeks. By integrating advanced tools from optics, biology, and computation, Cellino makes stem cell differentiation a digital process, allowing healthcare providers to efficiently produce functionally mature cells at scale. This innovative approach aims to enhance the accessibility of life-saving medicines for patients.

MycoWorks LLC specializes in the research, design, and manufacturing of sustainable leather alternatives derived from natural mycelium. Established in 2013 and based in San Francisco, the company produces a proprietary material called Reishi, which is water-resistant and customizable in texture and features. Reishi is designed to mimic the performance and feel of traditional leather while being animal-free and environmentally friendly. MycoWorks employs a unique platform known as Fine Mycelium to create this innovative biomaterial, which boasts qualities such as strength, durability, and biodegradability. The company aims to provide natural alternatives to conventional materials like plastic foams, textiles, and leather, catering to industries such as aerospace, automotive, apparel, and architectural interiors. Through its carbon-negative production process, MycoWorks offers a rapidly grown solution that aligns with sustainable design principles.

Metagenomi, Inc. is a genetic medicines company based in Emeryville, California, focused on developing innovative gene editing systems for the treatment of genetic diseases. Since its incorporation in 2016, the company has utilized a proprietary metagenomics-derived genome editing toolbox that enables the creation of curative therapeutics. This toolbox encompasses a range of advanced technologies, including programmable nucleases, base editors, and various RNA and DNA-mediated integration systems, such as prime editing systems and CRISPR-associated transposases (CASTs). Metagenomi aims to address the challenges posed by diverse mutations that have traditionally been difficult to target with existing genome engineering approaches.

Ansa Biotechnologies, Inc. is a biotechnology company based in Berkeley, California, focused on developing innovative DNA synthesis technology utilizing enzymes. Established in 2018, the company aims to improve upon traditional chemical methods of DNA synthesis that have remained largely unchanged for decades. Ansa's enzymatic approach offers significant advantages, including increased speed, accuracy, and cleanliness in the production of DNA fragments such as oligonucleotides. This technology enhances the capabilities of biological research, therapeutics, diagnostics, and biomanufacturing by enabling the synthesis of gene-length oligonucleotides. Through its advancements, Ansa Biotechnologies seeks to facilitate innovation in the fields of biological research and engineering, ultimately providing valuable services to medical researchers and contributing to the broader biotechnology landscape.

Geltor, Inc. produces bioactive animal free collagens and other proteins for beauty, nutrition, and other applications. It offers Collume, a bio-designed collagen technology for skincare cellular regeneration, protection, and derma-collagen synthesis; and HumaColl21, a collagen product that delivers collagen, elastin, laminin, and fibronectin boosting effect for skin care. The company also provides vegan collagen peptides and other novel proteins for functional food and nutraceutical formulas. Geltor, Inc. was incorporated in 2015 and is based in San Leandro, California.

Geltor, Inc. produces bioactive animal free collagens and other proteins for beauty, nutrition, and other applications. It offers Collume, a bio-designed collagen technology for skincare cellular regeneration, protection, and derma-collagen synthesis; and HumaColl21, a collagen product that delivers collagen, elastin, laminin, and fibronectin boosting effect for skin care. The company also provides vegan collagen peptides and other novel proteins for functional food and nutraceutical formulas. Geltor, Inc. was incorporated in 2015 and is based in San Leandro, California.

Ansa Biotechnologies, Inc. is a biotechnology company based in Berkeley, California, focused on developing innovative DNA synthesis technology utilizing enzymes. Established in 2018, the company aims to improve upon traditional chemical methods of DNA synthesis that have remained largely unchanged for decades. Ansa's enzymatic approach offers significant advantages, including increased speed, accuracy, and cleanliness in the production of DNA fragments such as oligonucleotides. This technology enhances the capabilities of biological research, therapeutics, diagnostics, and biomanufacturing by enabling the synthesis of gene-length oligonucleotides. Through its advancements, Ansa Biotechnologies seeks to facilitate innovation in the fields of biological research and engineering, ultimately providing valuable services to medical researchers and contributing to the broader biotechnology landscape.

Metagenomi, Inc. is a genetic medicines company based in Emeryville, California, focused on developing innovative gene editing systems for the treatment of genetic diseases. Since its incorporation in 2016, the company has utilized a proprietary metagenomics-derived genome editing toolbox that enables the creation of curative therapeutics. This toolbox encompasses a range of advanced technologies, including programmable nucleases, base editors, and various RNA and DNA-mediated integration systems, such as prime editing systems and CRISPR-associated transposases (CASTs). Metagenomi aims to address the challenges posed by diverse mutations that have traditionally been difficult to target with existing genome engineering approaches.